Long-term bone marrow culture data are the most powerful predictor of peripheral blood progenitor cell mobilization in healthy donors

被引:0
作者
López-Holgado, N
Pata, C
Villarón, E
Sánchez-Guijo, F
Alberca, M
Martín, A
Corral, M
Sánchez-Abarca, I
Pérez-Simón, JA
San Miguel, JF
del Cañizo, MC
机构
[1] Univ Salamanca, Hosp Clin, Dept Hematol, E-37008 Salamanca, Spain
[2] Hosp Virgen Concha, Dept Hematol, Zamora, Spain
关键词
healthy donors; long-term bone marrow cultures; CD34(+) cells; hematopoietic progenitor cells; mobilization;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background and Objectives. There is wide interindividual variation in progenitor cell mobilization. The present study was aimed to analyze steady state hematopoiesis in healthy donors and its influence on hematopoietic progenitor cell (HPC) mobilization. Design and Methods. Bone marrow (BM) was aspirated from 72 healthy donors prior to administration of recombinant human granuloyte colony-stimulating factor (G-CSF). Analyses of CD34(+) cells and semisolid cultures as well as long-term cultures were performed from BM or leukapheresis products. Results. Male donors showed a higher number of BFU-E (p=0.007) and committed progenitors (p=0.05), a better stromal layer (p=0.02), and higher long-term bone marrow culture (LT-BMC) counts (p < 0.05) when compared to those in female donors. When correlating the culture pattern of the BM with the data from the leukapheresis products, we observed that the number of the immature progenitors in BM correlated significantly with both the number of CD34(+) cells and CFU-GM in the first leukapheresis. Univariate analysis revealed that the following variables had a beneficial impact on the number of CD34(+) cells: male sex, body weight > 73 Kg, G-CSF schedule and results of LT-BMC, although in the multivariate analysis only the number of CFU-GM obtained after LT-BMC showed a significant influence (p < 0.001). Interpretation and Conclusions. These results confirm the interindividual variation in HPC mobilization among healthy subjects, with LT-BMC counts being the most reliable predictor, expressing the behavior of the immature progenitors and their relationship with the microenvironment.
引用
收藏
页码:353 / 359
页数:7
相关论文
共 26 条
[1]   Factors affecting mobilization of CD34+ cells in normal donors treated with filgrastim [J].
Anderlini, P ;
Przepiorka, D ;
Seong, C ;
Smith, TL ;
Huh, YO ;
Lauppe, J ;
Champlin, R ;
Korbling, M .
TRANSFUSION, 1997, 37 (05) :507-512
[2]   Allogeneic peripheral blood stem cell transplantation in patients with advanced hematologic malignancies: A retrospective comparison with marrow transplantation [J].
Bensinger, WI ;
Clift, R ;
Martin, P ;
Appelbaum, FR ;
Demirer, T ;
Gooley, T ;
Lilleby, K ;
Rowley, S ;
Sanders, J ;
Storb, R ;
Buckner, CD .
BLOOD, 1996, 88 (07) :2794-2800
[3]   Peripheral blood progenitor cell mobilization in healthy donors receiving recombinant human granulocyte colony-stimulating factor [J].
Carlo-Stella, C ;
Cesana, C ;
Regazzi, E ;
Falzetti, F ;
Aversa, F ;
Rizzoli, V ;
Martelli, M ;
Tabilio, A .
EXPERIMENTAL HEMATOLOGY, 2000, 28 (02) :216-224
[4]  
CHATTA GS, 1994, BLOOD, V84, P2923
[5]   Analysis of factors associated with low peripheral blood progenitor cell collection in normal donors [J].
de la Rubia, J ;
Arbona, C ;
de Arriba, F ;
del Cañizo, C ;
Brunet, S ;
Zamora, C ;
Díaz, MA ;
Bargay, J ;
Petit, J ;
de la Serna, J ;
Insunza, A ;
Arrieta, R ;
Pascual, MJ ;
Serrano, D ;
Sanjuan, I ;
Espigado, I ;
Alegre, A ;
Martínez, D ;
Verdeguer, A ;
Martínez, C ;
Benlloch, L ;
Sanz, MA .
TRANSFUSION, 2002, 42 (01) :4-9
[6]  
del Cañizo C, 1999, BONE MARROW TRANSPL, V23, P901
[7]   High- versus standard-dose filgrastim (rhG-CSF) for mobilization of peripheral-blood progenitor cells from allogeneic donors and CD34+ immunoselection [J].
Engelhardt, M ;
Bertz, H ;
Afting, M ;
Waller, CF ;
Finke, J .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (07) :2160-2172
[8]   Blood progenitor cell (BPC) mobilization studied in multiple myeloma, solid tumor and non-Hodgkin's lymphoma patients after combination chemotherapy and G-CSF [J].
Engelhardt, M ;
Winkler, J ;
Waller, C ;
Lange, W ;
Mertelsmann, R ;
Henschler, R .
BONE MARROW TRANSPLANTATION, 1997, 19 (06) :529-537
[9]   Analysis of stem cell apheresis products using intermediate-dose filgrastim plus large volume apheresis for allogeneic transplantation [J].
Engelhardt, M ;
Bertz, H ;
Wäsch, R ;
Finke, J .
ANNALS OF HEMATOLOGY, 2001, 80 (04) :201-208
[10]  
FAUSER AA, 1979, BLOOD, V53, P1023